On September 30, Inogen announced it is selling its U.S. oxygen rental business to Rotech Healthcare for up to $25 million in cash. In the same release, the board expanded the share buyback by $15 million to a total of $45 million, and Inogen signed a long term supply agreement that puts its concentrators into Rotech's national distribution network.
The headline got very little attention, which is typical for this stock. We think it's one of the most important moves management has made since we started building the position, and here's why.
The Part They Sold Was the Part That Was Shrinking
Inogen has three revenue streams: U.S. sales, international sales and U.S. rentals. Here's how each did in Q2:
| Q2 2026 | Revenue | YoY |
|---|---|---|
| International sales | $41.3M | +14.8% |
| U.S. sales | $42.3M | -2.3% |
| U.S. rentals | $11.6M | -11.8% |
| Total | $95.1M | +3.0% |
Rentals did $24.3 million in the first half of the year, down 9.8%, and were the one line consistently pulling the growth rate down. More than 60% of rental income has historically come from Medicare, and rising service costs have been eating into the benefit of reimbursement increases. It's a business that needs a lot of capital and service staff and depends on Medicare rates, sitting inside a company that wants to be a respiratory device innovator.
Take rentals out of Q2 and the remaining business did about $83.5 million, up roughly 5.5% year over year by our calculation. That's close to double the reported growth rate. Starting with Q3, Inogen expects to report rentals as discontinued operations, so the next earnings release should show that cleaner number instead of the blended 3%.
Management said it expects these transactions to improve both the revenue growth rate and adjusted operating income. They didn't give numbers yet. Those come with Q3.
The Supply Agreement With Rotech
Rotech isn't only buying the rental assets. Inogen also signed a long term supply agreement with Rotech.
Until now, Inogen was competing with home medical equipment providers like Rotech for rental patients while also trying to sell those same providers its equipment. With this deal, the rental patients go to a national HME that buys Inogen's concentrators to serve them. Inogen stops running the service operation, which carries lower margins, and keeps selling the hardware.
We wrote back in May that HMEs had grown to about 60% of new starts, up from 30 to 40% historically, and that the B2B channel carries better margins than selling direct. This deal goes further in that direction. CEO Kevin Smith said the company will focus on partnering with HME providers to reach more patients.
The Buyback Just Got Bigger
We've been watching Inogen buy back stock on the tape since spring. The filings confirmed it: 1,145,150 shares repurchased in the first half of 2026 for about $7.5 million, an average of around $6.55.
Once the deal closes, the authorization goes from $30 million to $45 million, running through June 30, 2028. Here's the setup once the cash comes in:
| Metric | Value |
|---|---|
| Cash and securities (end of Q2) | $106.8M |
| Debt | $0 |
| Rotech proceeds (up to) | $25M |
| Total buyback authorization | $45M |
| Price to sales | ~0.4x |
One correction worth making. Our May posts cited roughly $121 million in cash. That number is now $106.8 million, partly because of the buyback. Spending cash on buybacks at these prices is what we wanted management to do, so we're fine with the decline, but the post should reflect the current number.
Add up to $25 million on top and cash sits around $130 million, with the stock trading at roughly 0.4x sales. A $45 million authorization is large for a company this size. That buying has been supporting the stock, and now there's more of it.
Is $25 Million Too Cheap?
This is the fair pushback. The rental business annualizes to roughly $48 million in revenue, and Inogen sold it for up to $25 million, about half of one year's sales.
Our view is that the price reflects what the business was: shrinking by double digits, dependent on Medicare, with service costs rising faster than reimbursement. Nobody pays a growth multiple for that. What matters more is the effect on the rest of the company. A unit that was dragging down growth and using up capital and management attention turns into cash, a larger buyback and a distribution partner.
Two more caveats. "Up to" $25 million means the final number could come in lower. And we don't yet know how much rentals contributed to adjusted EBITDA. If rentals were carrying more of the profit than we think, near term earnings could look worse even as the growth rate improves. We should find out with Q3.
What We're Watching on the Q3 Call
Growth rate for continuing operations. Does the restated number land near our ~5.5% estimate, or better?
Margins without rentals. Rentals needed a lot of service work. If gross margin improves without them, the stock has a case for a higher valuation.
New guidance. The current $355 to $361 million revenue guidance includes rentals. The updated guidance for continuing operations is what analysts will rebuild their models on.
Buyback pace. How much of the expanded authorization gets used, and how fast.
Rotech volumes. Any detail on how large the supply agreement could become.
Where We Stand
We still hold a significant position. The core of the thesis hasn't changed: a company with no debt, a large cash balance relative to its market cap, new leadership, an activist on the board and a buyback absorbing shares. What this deal changes is what the next earnings release will show. For two years the problem with INGN was less the business itself and more that the stronger parts were hard to see in the consolidated numbers. Selling rentals makes them much easier to see.
We still think we're early rather than wrong, and Q3 should give us a better read.